MeningoFinder® 2SMART

Multiplex qualitative real‑time PCR kit for the rapid and specific diagnosis of meningitis and encephalitis, capable of detecting and differentiating 22 pathogens (4 RNA viruses, 8 DNA viruses, 8 bacteria and 2 fungi) in cerebrospinal fluid samples.

Product Description

The MeningoFinder® 2SMART kit is a high‑complexity qualitative in vitro diagnostic test that provides rapid identification of the causative agents of meningitis and encephalitis, critical pathologies associated with high mortality and morbidity rates. Its multiplex capacity allows drastically reducing diagnosis time, optimising the use of specific antimicrobial or antiviral treatments at a very early stage, and significantly improving patient survival and prognosis.

Its workflow consists of a pre‑amplification and two 2SMART reactions with reading via melting curve analysis, offering a rapid, sensitive and robust diagnostic workflow.

Detected Pathogens

RNA viruses: Mumps virus, measles virus, human Enterovirus (EV) and Parechovirus. DNA viruses: Herpes simplex virus 1 (HSV-1), Herpes simplex virus 2 (HSV-2), Varicella‑zoster virus (VZV), Epstein‑Barr virus (EBV), Cytomegalovirus (CMV) and Human herpesvirus 6, 7 and 8 (HHV-6, HHV-7, HHV-8). Bacteria: Listeria monocytogenes, Staphylococcus aureus, Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus agalactiae, Neisseria meningitidis, Borrelia burgdorferi sensu lato / Borrelia miyamotoi and Escherichia coli K1. Fungi: Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato.

Key Advantages and Features

Rapid and accurate diagnosis: Allows unambiguous differentiation between viral, bacterial or fungal aetiologies in cerebrospinal fluid (CSF) samples. Broad target coverage: Identification of up to 22 pathogens of high clinical relevance in a single sample. Safety and Quality Control: Includes MS2 bacteriophage internal control (IC) to monitor the extraction process and the presence of inhibitors, plus specific amplification controls (AC1 and AC2) and positive controls (PC). Validated samples: Cerebrospinal fluid (CSF). Extraction methods validated using NuclisENS® easyMAG® and QIAamp® cador® Pathogen Mini Kit. Professional Use: Specifically designed for qualified personnel in clinical and microbiological research laboratories.
×

Area:

Bacteria, Fungus, Microbiology, Virus
Consult our experts

Google reCaptcha: Invalid site key.

Related products

SureSelect Cancer CGP Assay

Targeted-enrichment NGS pan-cancer panel for comprehensive genomic profiling (CGP) of solid tumours. Designed to detect somatic variants at DNA level (SNVs, indels, CNVs, translocations) and RNA level (gene fusions), as well as to assess complex immuno-oncology biomarkers such as tumour mutational burden (TMB), microsatellite instability (MSI) and homologous recombination deficiency (HRD). Detailed Description Operating principle…
Agilent
Next Generation Sequencing (NGS)

SeqOne HRD Solution con Agilent SureSelect CD HRR17 Panel

HRD analysis solution combining low-coverage whole-genome sequencing (shallow/low-pass WGS) and a targeted gene panel to detect genomic instability, BRCA1/2 alterations and other genes related to homologous recombination. It is designed for laboratories wishing to implement HRD testing in-house with an automated, efficient and clinically validated workflow. Detailed Description SeqOne’s HRD solution combines shallow WGS and…
Agilent
Next Generation Sequencing (NGS)

OncoSELECT®

Comprehensive targeted liquid biopsy assay designed to support decision-making in oncology through the analysis of 74 clinically relevant genes. The solution encompasses everything from library preparation reagents to bioinformatics analysis, clinical interpretation and the generation of detailed reports. 3.- Detailed Description Operating principle OncoSELECT® is an advanced liquid biopsy panel based on circulating cell-free DNA…
OncoDNA
Next Generation Sequencing (NGS)

Agilent SureSelect Human All Exon V8.

High-performance exome for the enrichment of human coding regions, with updated coverage of RefSeq, CCDS and GENCODE, including the TERT promoter and difficult-to-capture exons. 3.- Detailed Description Operating principle SureSelect Human All Exon V8 is based on NGS library preparation and capture enrichment of target regions of the human exome. The workflow is compatible with…
Agilent
Next Generation Sequencing (NGS)